These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 35203713)
1. Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease. Aragona CO; Versace AG; Ioppolo C; La Rosa D; Lauro R; Tringali MC; Tomeo S; Ferlazzo G; Roberts WN; Bitto A; Irrera N; Bagnato G Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203713 [TBL] [Abstract][Full Text] [Related]
2. Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug. Kafle S; Thapa Magar M; Patel P; Poudel A; Cancarevic I Cureus; 2021 Jul; 13(7):e16404. PubMed ID: 34414042 [TBL] [Abstract][Full Text] [Related]
3. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Campochiaro C; Allanore Y Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331 [TBL] [Abstract][Full Text] [Related]
4. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. Fischer A; Patel NM; Volkmann ER Open Access Rheumatol; 2019; 11():283-307. PubMed ID: 31849543 [TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Ueda T; Sakagami T; Kikuchi T; Takada T Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675 [TBL] [Abstract][Full Text] [Related]
7. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399 [TBL] [Abstract][Full Text] [Related]
8. Interstitial Lung Disease Associated with Systemic Sclerosis. Mismetti V; Si-Mohamed S; Cottin V Semin Respir Crit Care Med; 2024 Jun; 45(3):342-364. PubMed ID: 38714203 [TBL] [Abstract][Full Text] [Related]
9. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Lamb YN Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946 [TBL] [Abstract][Full Text] [Related]
11. Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists. Ferrari HM; Kale-Pradhan P; Konja J; Dierker M; Martirosov AL Ann Pharmacother; 2023 Dec; ():10600280231213672. PubMed ID: 38095621 [TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Cottin V; Brown KK Respir Res; 2019 Jan; 20(1):13. PubMed ID: 30658650 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM; Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120 [TBL] [Abstract][Full Text] [Related]
18. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M Front Immunol; 2020; 11():1990. PubMed ID: 33013852 [TBL] [Abstract][Full Text] [Related]
19. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Yamasaki Y; Kuwana M Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975 [TBL] [Abstract][Full Text] [Related]
20. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Campochiaro C; Lazzaroni MG; Bruni C; Zanatta E; De Luca G; Matucci-Cerinic M Ther Adv Musculoskelet Dis; 2022; 14():1759720X221116408. PubMed ID: 36051631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]